Ask AI

Next-Generation Approaches for Relapsed/Refractory Multiple Myeloma: A Focus on Novel Therapeutic Targets and Pathways

In this online program based on a symposium from EHA 2025, experts discuss emerging uses of CELMoDs for treating patients with relapsed/refractory multiple myeloma. Download slides, view an on-demand webcast, and read an expert commentary for more information on this topic.

Share

Program Content

Activities

Novel Protein Degraders for MM
Key Data and Ongoing Trials With Novel Protein Degraders in Multiple Myeloma
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 11, 2025

Novel Approaches to MM Treatment
Next-Generation Approaches for Relapsed/Refractory Multiple Myeloma: A Focus on Novel Protein Degraders
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 11, 2025

Protein Degradation in MM
The Rationale for Targeting Protein Degradation Pathways in Myeloma
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 11, 2025

Activities

Novel Therapeutic Targets for RR MM
Next-Generation Approaches for Relapsed Refractory Multiple Myeloma: A Focus on Novel Therapeutic Targets and Pathways
Video
Congratulations: You achieved a completion on 04/09/2022

Released: July 17, 2025

Expires: January 16, 2026

Activities

CELMoDs for MM
How Do CELMoDs Work for Multiple Myeloma?
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: August 13, 2025

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC.

Supporters

Supported by an educational grant from Bristol Myers Squibb.

Bristol Myers Squibb